Tag: Kansas Bioscience Authority (KBA)
Keith Harrington isn’t looking for hockey-stick growth companies. With the new fund he’s co-leading — Novel Growth Partners — Harrington wants to invest in small, steadily-growing tech companies in the Midwest. But instead of a traditional venture capital model, Novel is employing a revenue-based finance model that should appeal to more entrepreneurs, Harrington said. “We believe that…
Read More >
A formerly state-backed investment organization for Kansas bioscience businesses will soon be transitioning from a public to private organization. After dwindling support from the State of Kansas, the Kansas Bioscience Authority’s board recently voted unanimously to shift the organization to the private market in 2016, allowing portfolio companies to partner with investors in the private…
Read More >
Olathe-based Metactive Medical recently secured a grant that will continue the development of its embolization device that fights cancer. The National Institutes of Health awarded Metactive $224,000 that will fund nonclinical studies on the performance of the company’s Blockstent Microcatheter embolic devices for the occlusion — or blockage — of peripheral arteries and veins. “We believe…
Read More >
A bill in the Kansas legislature if passed would dissolve the Kansas Bioscience Authority, which has recently served as a venture capital organization investing in early-stage bioscience firms. The measure — SB 305 — would shut down the organization and transfer its funds and obligations to the Kansas Department of Commence. Proponents of the KBA say…
Read More >
Flow Forward Medical boosted its latest funding round to further develop its device that helps improve outcomes for hemodialysis patients. The Olathe-based company closed a $1.3 million round of additional Series A financing led by the Kansas Bioscience Authority. Flow Forward previously raised $4.4 million, bringing its total funding raised to date to about $5.7 million.…
Read More >
